This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.

Unlock the details of this groundbreaking opportunity here...

Charles Alpuche Biography and Net Worth

COO of Insulet

Mr. Alpuche has served as our Executive Vice President and Chief Operating Officer since February 2019. Prior, he served as our: Executive Vice President and Chief Operations Officer from February 2018 to February 2019; Executive Vice President, Global Manufacturing and Operations from February 2017 to February 2018; and Senior Vice President, Global Manufacturing and Operations from February 2016 to February 2017. From 2012 to February 2016, Mr. Alpuche served as an independent consultant for both domestic and international companies in the food, beverage and chemical industries. Previously, he spent thirty years at PepsiCo in leadership roles of increasing responsibility overseeing domestic and international plant operations. Earlier in his career at PepsiCo, he held a number of management roles in plant operations, product management and quality control. Most recently, he served as PepsiCo’s Senior Vice President of North America Beverages, and before that he held the position of Vice President and General Manager, Concentrate Operations, Asia and Americas. Mr. Alpuche holds a Bachelor of Science in Business Administration from Delaware Valley College and obtained an Executive Master of Science in Organizational Management from the University of Pennsylvania.

What is Charles Alpuche's net worth?: The estimated net worth of Charles Alpuche is at least $7.48 million as of March 13th, 2023. Mr. Alpuche owns 45,584 shares of Insulet stock worth more than $7,483,525 as of April 25th. This net worth estimate does not reflect any other investments that Mr. Alpuche may own. Learn More about Charles Alpuche's net worth.
How do I contact Charles Alpuche?: The corporate mailing address for Mr. Alpuche and other Insulet executives is 100 NAGOG PARK, ACTON MA, 01720. Insulet can also be reached via phone at (978) 600-7000 and via email at [email protected]. Learn More on Charles Alpuche's contact information.
Has Charles Alpuche been buying or selling shares of Insulet?: Charles Alpuche has not been actively trading shares of Insulet during the last quarter. Most recently, Charles Alpuche sold 23,401 shares of the business's stock in a transaction on Monday, March 13th. The shares were sold at an average price of $305.15, for a transaction totalling $7,140,815.15. Following the completion of the sale, the insider now directly owns 45,584 shares of the company's stock, valued at $13,909,957.60. Learn More on Charles Alpuche's trading history.
Who are Insulet's active insiders?: Insulet's insider roster includes Charles Alpuche (COO), Eric Benjamin (SVP), Luciana Borio (Director), Bret Christensen (EVP), Sally Crawford (Director), John Fallon (Director), James Hollingshead (CEO), Dan Manea (SVP), Wayde McMillan (CFO), Shacey Petrovic (CEO), Prem Singh (SVP), and Michael Spears (SVP). Learn More on Insulet's active insiders.
Are insiders buying or selling shares of Insulet?: In the last twelve months, Insulet insiders bought shares 2 times. They purchased a total of 5,551 shares worth more than $1,006,994.42. In the last twelve months, insiders at the medical instruments supplier sold shares 6 times. They sold a total of 48,672 shares worth more than $9,836,499.00. The most recent insider tranaction occured on February, 28th when Director Shacey Petrovic sold 11,609 shares worth more than $1,891,338.28. Insiders at Insulet own 0.9% of the company. Learn More about insider trades at Insulet.
Information on this page was last updated on 2/28/2024.

Charles Alpuche Insider Trading History at Insulet

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/13/2023	Sell	23,401	$305.15	$7,140,815.15	45,584
3/9/2023	Sell	4,000	$290.90	$1,163,600.00	45,584
2/28/2023	Sell	4,000	$278.82	$1,115,280.00	45,584
6/6/2022	Sell	6,000	$215.32	$1,291,920.00	43,899
6/2/2021	Sell	1,900	$262.67	$499,073.00
9/1/2020	Sell	3,415	$220.11	$751,675.65
5/15/2019	Sell	3,900	$104.78	$408,642.00
3/15/2018	Sell	7,090	$84.65	$600,168.50
9/6/2017	Buy	2,500	$58.08	$145,200.00
12/9/2016	Buy	6,600	$37.70	$248,820.00

Charles Alpuche Buying and Selling Activity at Insulet

Insulet Company Overview

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Today's Range

Now: $164.17

$160.38

$166.64

50 Day Range

MA: $172.00

$163.25

$197.14

2 Week Range

Now: $164.17

$125.82

$335.91

Volume

864,262 shs

Average Volume

865,179 shs

Market Capitalization

$11.50 billion

P/E Ratio

56.42

Dividend Yield

N/A

Beta

0.98

Jim Cramer’s “The Biggest Drug Ever”

From Behind the Markets | Ad